

May 8, 2017

**For Immediate Release**

Company name Otsuka Holdings Co., Ltd.  
Representative Tatsuo Higuchi  
President and Representative Director, CEO  
Code number 4578 First Section , Tokyo Stock Exchange  
Inquiries Yuji Kogure  
Director, Investors Relations Department

**Otsuka Pharmaceutical Factory,  
enters into an agreement to acquire additional equity in its joint venture subsidiary,  
Otsuka Pharmaceutical India Private Limited (OPI)**

Otsuka Pharmaceutical Factory, Inc. (OPF), which holds 60% equity in the Indian joint venture subsidiary, Otsuka Pharmaceutical India Private Limited\* (OPI), has reached an agreement to acquire all the OPI shares held by Claris Lifesciences Limited (Claris) (20% of outstanding shares). To this extent, the two companies have signed a Stock Purchase Agreement. The shareholding ratio after the purchase of the shares will be OPF: 80% and Mitsui and Company (Mitsui): 20%. The share transfer is subject to the approval of FIPB (Foreign Investment Promotion Board of India).

On July 31, 2013, OPF, together with Claris and Mitsui, has established a joint venture company, and since then, OPI has been operating its iv solutions business based on the business transferred from Claris.

With this increase in the shareholdings of OPI, OPF will be able to maximize the utilization of the technology of basic iv solution and clinical nutrition that it has acquired throughout the years in Japan, and will strengthen its business in India, a country in which significant economic growth and increasingly sophisticated healthcare system are expected.

Going forward, under Otsuka Group's corporate philosophy, "Otsuka-people creating new products for better health worldwide," OPF with its partner Mitsui will contribute to the betterment of health of the people of India.

\* OPI has changed its name from Claris Otsuka Private Limited to Otsuka Pharmaceutical India Private Limited on March 1, 2017.

## Company Profile

### Otsuka Pharmaceutical India Private Limited

Date of Establishment of the Joint Venture	:	July 31, 2013
Capital Investment Ratio	:	10.524 billion INR (approximately 17.9 billion JPY) (Before Share Transfer) OPF: 60%, Claris: 20%, Mitsui: 20% (After Share Transfer) OPF: 80%, Mitsui: 20%
Representative	:	Shuichi Takagi, CEO
Head office	:	Ahmedabad, Gujarat, India
Employees	:	1,059 (as of December 31, 2016)
Scope of Business	:	Manufacture and distribution of basic solution and clinical nutrition products
Business Area	:	India and over 50 countries worldwide
Website (URL)	:	<a href="http://www.otsukapharma.in/">http://www.otsukapharma.in/</a>

### Otsuka Pharmaceutical Factory, Inc.

Established	:	October 7, 1969
Capital	:	80 million yen
Representative	:	Ichiro Otsuka, President
Head office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima, Japan
Employees	:	2,309 (as of December 31, 2016)
Scope of Business	:	Manufacture and sale of pharmaceutical and nutritional products
Website (URL)	:	<a href="http://www.otsukakj.jp/en/">http://www.otsukakj.jp/en/</a>